FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Registration Date 9 Nov 2016
Share

BioCLIA

(0)

Medicine Pharmaceuticals

Chemiluminescent Immunoassay

Applications

Cancer chemotherapy

Properties

Master calibration curve Two-point calibration Onboard reagents stable for 4-8 weeks Broad dynamic range High sensitivity Quantitative and reproducible results

High sensitivity

Manufacturer's Description

BioCLIA, the recently launched fully automated and random-access platform, has a test menu of 43 autoantibody assays on board, which is ever-expanding to cover allergy, autoimmune, thyroid, cancer markers as the most comprehensive testing menu.
BioCLIA assays implement the magnetic microparticle and Chemiluminescence technology that offers a broad dynamic range and high precision that is superior to the traditional ELISA technology, and thus provides quantitative results with premium detection sensitivity and measurement precision that aid in the diagnosis of autoimmune, allergic, thyroid diseases, and cancer.